Wednesday, 05 August 2026 07:00 AM
Company Update
The addition of Foundayo (orforglipron) provides participants with an FDA-approved, injection-free, GLP-1 treatment for people living with excess weight within a structured personalized care platform
NEW YORK CITY, NY / ACCESS Newswire / August 5, 2026 / Onsera Health, a comprehensive, AI-driven cardiometabolic and weight management solution, announced that it is offering access to Eli Lilly's obesity management medications, Zepbound® (tirzepatide) and once-daily, oral, Foundayo, providing more optionality with FDA-approved GLP-1 treatments for adults living with obesity, overweight or weight-related cardiometabolic medical concerns.
Through Onsera Health, eligible participants will be able to access Eli Lilly's GLP-1 medications with a prescription from one of Onsera's board-certified physicians, alongside clinically integrated, data-driven care that provides clear structure and ongoing guidance, adapting with participants as they go, supporting individual health outcomes.
For employers facing rising healthcare costs, Onsera is the cardiometabolic care platform that predicts population health risk-and takes steps aimed at reducing it-through personalized clinical care, integrated GLP-1 access, and a structured 24-month course of care. For participants interested in and eligible for once-daily, injection-free, Foundayo, pricing is fixed at $399 per month. For Zepbound, pricing is fixed at $449 per month. Onsera provides flexible program customization for employers and trusts, including eligibility criteria, prescription co-pay structure, medication coverage, integration with existing health plans and pharmacy benefit managers, and population-specific configurations to balance access, employee experience, and financial sustainability.
"With this new offering, including both Zepbound and Foundayo, we are providing employers' covered lives and members with greater choice and flexibility to support their personal weight loss and cardiometabolic goals," said Dr. Kristin Baier, Chief Medical Officer, Onsera Health. "Not only are we providing our participants with more FDA-approved treatment options, but we're ensuring that those GLP-1 treatments are delivered thoughtfully and seamlessly to support the individual participant experience with behavioral and lifestyle interventions, while managing health outcomes and costs over time."
Once participants fill a prescription through Onsera's easy-to-navigate mobile app, the prescription is shipped directly to the participant's address on file. From there, participants receive comprehensive, coordinated medical management including obesity-trained, board-certified physicians, registered nurses, registered dietitians and health coaches to continuously support the journey, inclusive of continuous tracking of medication adherence and physiological response to support sustained outcomes and long-term ROI.
This offering of Eli Lilly's FDA-approved GLP-1 treatments underscores Onsera's commitment to the latest evidence-based clinical therapies while delivering measurable outcomes through adaptive, personalized care.
About Onsera Health:
Onsera Health is an evidence-based cardiometabolic and weight management care platform and healthcare provider for employers, union trusts and health plans, helping organizations move from reactive claims management toward preventive, outcomes-oriented strategies for improving healthspan. Backed by decades of clinical research, cardiovascular and metabolic drug developments and scientific rigor, Onsera delivers advanced analytics, coordinated clinical care, and affordable medication access, including GLP-1s, into one seamless AI-powered model with the goal of supporting risk reduction, managing healthcare costs, and promoting long-term health and well-being for participants. For more information, visit onserahealth.com.
Contact Information:
Haley Ashcom
(412) 580-9334
[email protected]
SOURCE: Onsera Health